相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Respiratory Syncytial Virus Modified by Deletions of the NS2 Gene and Amino Acid S1313 of the L Polymerase Protein Is a Temperature-Sensitive, Live-Attenuated Vaccine Candidate That Is Phenotypically Stable at Physiological Temperature
Cindy Luongo et al.
JOURNAL OF VIROLOGY (2013)
Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease
Patricia A. Jorquera et al.
PLOS ONE (2013)
Increased Genetic and Phenotypic Stability of a Promising Live-Attenuated Respiratory Syncytial Virus Vaccine Candidate by Reverse Genetics
Cindy Luongo et al.
JOURNAL OF VIROLOGY (2012)
Nucleoprotein Nanostructures Combined with Adjuvants Adapted to the Neonatal Immune Context: A Candidate Mucosal RSV Vaccine
Aude Remot et al.
PLOS ONE (2012)
Respiratory Syncytial Virus Fusion Glycoprotein Expressed in Insect Cells Form Protein Nanoparticles That Induce Protective Immunity in Cotton Rats
Gale Smith et al.
PLOS ONE (2012)
Combination Therapy Using Monoclonal Antibodies against Respiratory Syncytial Virus (RSV) G Glycoprotein Protects from RSV Disease in BALB/c Mice
Hayat Caidi et al.
PLOS ONE (2012)
Respiratory Syncytial Virus-associated Hospitalizations Among Infants and Young Children in the United States, 1997-2006
Lauren J. Stockman et al.
PEDIATRIC INFECTIOUS DISEASE JOURNAL (2012)
Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention
Margarita Magro et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens
L. R. Stanberry et al.
VACCINE (2012)
Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles
S. Garlapati et al.
VACCINE (2012)
Sendai virus-based RSV vaccine protects African green monkeys from RSV infection
Bart G. Jones et al.
VACCINE (2012)
Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration
Aalzen de Haan et al.
VACCINE (2012)
Nonclinical phenotypic and genotypic analyses of a Phase 1 pediatric respiratory syncytial virus vaccine candidate MEDI-559 (rA2cp248/404/1030ΔSH) at permissive and non-permissive temperatures
Jeanne H. Schickli et al.
VIRUS RESEARCH (2012)
Respiratory syncytial virus vaccine development
Julia L. Hurwitz
EXPERT REVIEW OF VACCINES (2011)
Use of defined TLR ligands as adjuvants within human vaccines
Malcolm S. Duthie et al.
IMMUNOLOGICAL REVIEWS (2011)
Nanobodies® Specific for Respiratory Syncytial Virus Fusion Protein Protect Against Infection by Inhibition of Fusion
Bert Schepens et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Identification of nucleolin as a cellular receptor for human respiratory syncytial virus
Farnoosh Tayyari et al.
NATURE MEDICINE (2011)
A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease
Dennis M. Lindell et al.
PLOS ONE (2011)
Therapeutic targeting of respiratory syncytial virus G-protein
Lawrence M. Kauvar et al.
IMMUNOTHERAPY (2010)
Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice
Wenliang Zhang et al.
JOURNAL OF VIROLOGY (2010)
Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis
Harish Nair et al.
LANCET (2010)
Induction of immune response to the 17 kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine
P. E. Makidon et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2010)
Motavizumab for Prophylaxis of Respiratory Syncytial Virus in High-Risk Children: A Noninferiority Trial
Xavier Carbonell-Estrany et al.
PEDIATRICS (2010)
Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation
Toon Stegmann et al.
VACCINE (2010)
Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice
Lia M. Haynes et al.
JOURNAL OF INFECTIOUS DISEASES (2009)
Protective Efficacy and Immunogenicity of an Adenoviral Vector Vaccine Encoding the Codon-Optimized F Protein of Respiratory Syncytial Virus
Rebekka Kohlmann et al.
JOURNAL OF VIROLOGY (2009)
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
Maria Florencia Delgado et al.
NATURE MEDICINE (2009)
The Burden of Respiratory Syncytial Virus Infection in Young Children
Caroline Breese Hall et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine
Paul E. Makidon et al.
PLOS ONE (2008)
Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats
Hoyin Mok et al.
JOURNAL OF VIROLOGY (2007)
Aging and CD8+ T cell immunity to respiratory virus infections
Kenneth H. Ely et al.
EXPERIMENTAL GERONTOLOGY (2007)
Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease
Elaine M. Castilow et al.
IMMUNOLOGIC RESEARCH (2007)
Respiratory syncytial virus infection in elderly and high-risk adults
AR Falsey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants
RA Karron et al.
JOURNAL OF INFECTIOUS DISEASES (2005)
Economic impact of respiratory syncytial virus-related illness in the US - An analysis of national databases
LC Paramore et al.
PHARMACOECONOMICS (2004)
Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells
R Malhotra et al.
MICROBES AND INFECTION (2003)
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein
RA Tripp et al.
NATURE IMMUNOLOGY (2001)
Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection
AK Behera et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997
DK Shay et al.
JOURNAL OF INFECTIOUS DISEASES (2001)
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus
EA Kurt-Jones et al.
NATURE IMMUNOLOGY (2000)
Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees
MN Teng et al.
JOURNAL OF VIROLOGY (2000)
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults
IM Gonzalez et al.
VACCINE (2000)
分享论文
